| Dr Maya P Strange, MD | |
|
1 S. Prospect St., Arnold 3, Uvm Medical Center, Psychiatry/child Psych., Burlington, VT 05401 | |
| (802) 847-4563 | |
| (802) 847-7998 |
| Full Name | Dr Maya P Strange |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 23 Years |
| Location | 1 S. Prospect St., Arnold 3, Burlington, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740253178 | NPI | - | NPPES |
| 100509662 | Medicaid | NV |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Vermont Medical Center Inc | 9335138817 | 204 |
| University Of Vermont Medical Center Inc | 3779491071 | 994 |
News Archive
The US Department of Justice has honored Dr. Laura Mosqueda and UC Irvine's Elder Abuse Forensic Center with a 2011 Award for Professional Innovation in Victim Services.
Researchers have found an unexpected synergy between a T-cell stimulatory protein - the ICOS ligand - and interleukin-10, an immunoregulatory cytokine, to prevent inflammatory bowel disease in mice.
"[A] new and complementary agreement between Liberia and USAID, called the Fixed Amount Reimbursement Agreement (FARA)," is "quite revolutionary," Amanda Glassman, director of global health policy and a research fellow at the Center for Global Development (CGD), and Jacob Hughes, write in CGD's "Global Health Policy" blog.
AstraZeneca announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for ticagrelor (BRILINTA™).
› Verified 3 days ago
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
The US Department of Justice has honored Dr. Laura Mosqueda and UC Irvine's Elder Abuse Forensic Center with a 2011 Award for Professional Innovation in Victim Services.
Researchers have found an unexpected synergy between a T-cell stimulatory protein - the ICOS ligand - and interleukin-10, an immunoregulatory cytokine, to prevent inflammatory bowel disease in mice.
"[A] new and complementary agreement between Liberia and USAID, called the Fixed Amount Reimbursement Agreement (FARA)," is "quite revolutionary," Amanda Glassman, director of global health policy and a research fellow at the Center for Global Development (CGD), and Jacob Hughes, write in CGD's "Global Health Policy" blog.
AstraZeneca announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for ticagrelor (BRILINTA™).
› Verified 3 days ago
| Entity Name | Central Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831374362 PECOS PAC ID: 9335138817 Enrollment ID: O20040510001034 |
News Archive
The US Department of Justice has honored Dr. Laura Mosqueda and UC Irvine's Elder Abuse Forensic Center with a 2011 Award for Professional Innovation in Victim Services.
Researchers have found an unexpected synergy between a T-cell stimulatory protein - the ICOS ligand - and interleukin-10, an immunoregulatory cytokine, to prevent inflammatory bowel disease in mice.
"[A] new and complementary agreement between Liberia and USAID, called the Fixed Amount Reimbursement Agreement (FARA)," is "quite revolutionary," Amanda Glassman, director of global health policy and a research fellow at the Center for Global Development (CGD), and Jacob Hughes, write in CGD's "Global Health Policy" blog.
AstraZeneca announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for ticagrelor (BRILINTA™).
› Verified 3 days ago
| Entity Name | Central Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023028784 PECOS PAC ID: 9335138817 Enrollment ID: O20051220000393 |
News Archive
The US Department of Justice has honored Dr. Laura Mosqueda and UC Irvine's Elder Abuse Forensic Center with a 2011 Award for Professional Innovation in Victim Services.
Researchers have found an unexpected synergy between a T-cell stimulatory protein - the ICOS ligand - and interleukin-10, an immunoregulatory cytokine, to prevent inflammatory bowel disease in mice.
"[A] new and complementary agreement between Liberia and USAID, called the Fixed Amount Reimbursement Agreement (FARA)," is "quite revolutionary," Amanda Glassman, director of global health policy and a research fellow at the Center for Global Development (CGD), and Jacob Hughes, write in CGD's "Global Health Policy" blog.
AstraZeneca announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for ticagrelor (BRILINTA™).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Maya P Strange, MD 1 S. Prospect St., Arnold 3, Uvm Medical Center, Psychiatry/child Psych., Burlington, VT 05401 Ph: (802) 847-4563 | Dr Maya P Strange, MD 1 S. Prospect St., Arnold 3, Uvm Medical Center, Psychiatry/child Psych., Burlington, VT 05401 Ph: (802) 847-4563 |
News Archive
The US Department of Justice has honored Dr. Laura Mosqueda and UC Irvine's Elder Abuse Forensic Center with a 2011 Award for Professional Innovation in Victim Services.
Researchers have found an unexpected synergy between a T-cell stimulatory protein - the ICOS ligand - and interleukin-10, an immunoregulatory cytokine, to prevent inflammatory bowel disease in mice.
"[A] new and complementary agreement between Liberia and USAID, called the Fixed Amount Reimbursement Agreement (FARA)," is "quite revolutionary," Amanda Glassman, director of global health policy and a research fellow at the Center for Global Development (CGD), and Jacob Hughes, write in CGD's "Global Health Policy" blog.
AstraZeneca announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for ticagrelor (BRILINTA™).
› Verified 3 days ago
Rebecca Burch, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1 S Prospect St, Burlington, VT 05401 Phone: 802-847-4589 | |
Dr. Dhruv Shah, DO Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Judith L Lewis, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Avenue, Fletcher Allen Health Care, Burlington, VT 05401 Phone: 804-847-2791 Fax: 802-847-2733 | |
Ms. Laura Lynn Sponseller, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 111 Colchester Ave, Fahc Department Of Psychiatry, Patrick 4, Burlington, VT 05401 Phone: 802-829-9645 | |
Lisa Deuel Baker, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1 S Prospect St, Burlington, VT 05401 Phone: 802-847-4589 | |
Dr. Robert A Pierattini, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1 S Prospect St, Burlington, VT 05401 Phone: 802-847-4560 Fax: 802-847-8747 | |
Dr. Edward George Boyer Iv, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-4589 |